Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Indiana Blood and Marrow Transplantation, Site #138
mi
from
Indianapolis, IN
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Indiana Blood and Marrow Transplantation, Site #138
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Montefiore
mi
from
Bronx, NY
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
West Penn Allegheny Cancer Institute
mi
from
Pittsburgh, PA
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
West Penn Allegheny Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Mount Sinai
mi
from
Miami Beach, FL
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Mount Sinai
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
University of Alberta Hospital
mi
from
Edmonton,
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
University of Alberta Hospital
mi
from
Edmonton,
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Compassionate Cancer Care Research Group
mi
from
Fountain Valley, CA
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Compassionate Cancer Care Research Group
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Boca Raton Clinical Research
mi
from
Boca Raton, FL
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Boca Raton Clinical Research
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Monter Cancer Center
mi
from
Lake Success, NY
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Sciences University
mi
from
Portland, OR
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Charleston Hematology/Oncology Associates, Pa
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Baylor Scott and White University Medical Center
mi
from
Dallas, TX
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Baylor Scott and White University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Michigan Center of Medical Research
mi
from
Farmington Hills, MI
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Michigan Center of Medical Research
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Study of ASTX727 vs IV Decitabine in MDS and CMML
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  12/31/1969
James Graham Brown Cancer Center
mi
from
Louisville, KY
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 12/31/1969
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
Click here to add this to my saved trials
Stem Cell Transplantation for Patients With Cancers of the Blood
Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Stem Cell Transplantation for Patients With Cancers of the Blood
Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center
mi
from
San Francisco, CA
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato
mi
from
Heidelberg,
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato
mi
from
Heidelberg,
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Click here to add this to my saved trials
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated:  12/31/1969
Appalachian Regional Healthcare, INC
mi
from
Hazard, KY
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated: 12/31/1969
Appalachian Regional Healthcare, INC
mi
from
Hazard, KY
Click here to add this to my saved trials
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated:  12/31/1969
UZ Leuven
mi
from
Leuven,
Ixazomib Rollover Study
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Status: Enrolling
Updated: 12/31/1969
UZ Leuven
mi
from
Leuven,
Click here to add this to my saved trials